article thumbnail

Small glowing protein allows researchers to peer deeper into living tissues

Medical Xpress

Biomedical and genetic engineers at Duke University and the Albert Einstein College of Medicine have designed a small fluorescent protein that emits and absorbs light that penetrates deep into biological tissue.

Protein 75
article thumbnail

Recurrent brain trauma may increase Alzheimer's risk

Medical Xpress

New research finds that the brains of otherwise healthy military personnel who are exposed to explosions show an abnormal brain accumulation of amyloid-beta protein—a protein that plays a role in the development of Alzheimer's disease. The results of the study were published today in Radiology.

Radiology 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ginkgo Bioworks awarded DARPA contract for therapeutic proteins 

Drug Discovery World

The Defense Advanced Research Projects Agency (DARPA) has announced that Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has been awarded a four-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins.

Protein 52
article thumbnail

News from AACR 2024: Sunday’s highlights

Drug Discovery World

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science.

In-Vivo 52
article thumbnail

Mathematical model can speed up Alzheimer’s drug development

Drug Discovery World

Researchers have created a mathematical model that can accurately depict Alzheimer’s disease progression in individual patients, paving the way for personalised treatment and faster development of therapies. The researchers expect their model will be ready for use in a clinical setting within five years.

article thumbnail

AZD1222 US Phase III primary analysis confirms safety and efficacy

The Pharma Data

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. The Phase III D8110C00001 trial is part of this funding agreement. JPEO-CBRND.

article thumbnail

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

The Pharma Data

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. The Phase III D8110C00001 trial is part of this funding agreement. JPEO-CBRND.

Trials 52